(IBDQ) iShares iBonds Dec 2025 - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46434VBD10 • Target Maturity
IBDQ: High-Quality, Corporate, Bonds, Maturity, 2025
The iShares iBonds Dec 2025 Term Corporate ETF (NYSE ARCA:IBDQ) is a target maturity exchange-traded fund designed to invest in U.S. dollar-denominated, taxable, investment-grade corporate bonds with maturities between January 1, 2025, and December 15, 2025. The fund adheres to strict investment criteria, allocating at least 80% of its assets to the component securities of its underlying index and at least 90% to fixed income securities of the types included in the index. This structured approach ensures alignment with the funds investment objective of tracking the performance of the underlying index.
As of the latest data, the fund has approximately $3.14 billion in assets under management (AUM), demonstrating its popularity among investors seeking exposure to corporate bonds maturing in 2025. The ETFs average trading volume over the past 20 days is around 455,100 shares, indicating moderate liquidity. Its current price of $25.16 reflects the net asset value (NAV) of the underlying bonds, which are nearing their maturity dates.
From a technical perspective, the ETFs price action shows stability, with its 20-day and 50-day simple moving averages (SMA) at $25.09 and $25.04, respectively, closely tracking the current price. The 200-day SMA of $24.69 suggests a gradual upward trend over the past year. The average true range (ATR) of 0.02 indicates low volatility, consistent with the nature of short-duration fixed income securities.
Based on the provided technical and fundamental data, here is a 3-month forecast for the iShares iBonds Dec 2025 Term Corporate ETF (IBDQ):
Over the next three months, IBDQ is expected to trade within a narrow range, reflecting its low volatility and the approaching maturity of its underlying bonds. The price is likely to remain stable, oscillating between $25.00 and $25.30, supported by the convergence of its 20-day and 50-day SMAs near current levels. The funds AUM and average daily volume are expected to remain consistent, as investors continue to seek predictable returns from maturing corporate bonds.
Additional Sources for IBDQ ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IBDQ ETF Overview
Market Cap in USD | 3,076m |
Category | Target Maturity |
TER | 0.10% |
IPO / Inception | 2015-03-11 |
IBDQ ETF Ratings
Growth Rating | 37.9 |
Fundamental | - |
Dividend Rating | 67.6 |
Rel. Strength | -4.67 |
Analysts | - |
Fair Price Momentum | 24.56 USD |
Fair Price DCF | - |
IBDQ Dividends
Dividend Yield 12m | 3.96% |
Yield on Cost 5y | 4.36% |
Annual Growth 5y | 6.76% |
Payout Consistency | 94.8% |
IBDQ Growth Ratios
Growth Correlation 3m | 98.3% |
Growth Correlation 12m | 100% |
Growth Correlation 5y | 20.4% |
CAGR 5y | 2.22% |
CAGR/Max DD 5y | 0.23 |
Sharpe Ratio 12m | 8.53 |
Alpha | 1.26 |
Beta | 0.003 |
Volatility | 0.89% |
Current Volume | 392.1k |
Average Volume 20d | 376.5k |
As of May 09, 2025, the stock is trading at USD 25.11 with a total of 392,124 shares traded.
Over the past week, the price has changed by +0.12%, over one month by +0.63%, over three months by +1.10% and over the past year by +5.47%.
Partly, yes. Based on ValueRay Analyses, iShares iBonds Dec 2025 (NYSE ARCA:IBDQ) is currently (May 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 37.93 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBDQ as of May 2025 is 24.56. This means that IBDQ is currently overvalued and has a potential downside of -2.19%.
iShares iBonds Dec 2025 has no consensus analysts rating.
According to ValueRays Forecast Model, IBDQ iShares iBonds Dec 2025 will be worth about 26.5 in May 2026. The stock is currently trading at 25.11. This means that the stock has a potential upside of +5.62%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 26.5 | 5.6% |